1. Weetman, AP. Graves’ disease. N Engl J Med 2000; 17: 1236–1248.
Google Scholar | Crossref2. Ando, T, Latif, R, Davies, TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract Res Clin Endocrinol Metab 2005; 19: 33–52.
Google Scholar | Crossref | Medline3. Morshed, SA, Davies, TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res 2015; 47: 727–734.
Google Scholar | Crossref | Medline4. Ajjan, RA, Weetman, AP. Techniques to quantify TSH receptor antibodies. Nat Clin Pract Endocrinol Metab 2008; 4: 461–468.
Google Scholar | Crossref | Medline5. Ross, DS, Burch, HB, Cooper, DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343–1421.
Google Scholar | Crossref | Medline6. Lytton, SD, Ponto, KA, Kanitz, M, et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123–2131.
Google Scholar | Crossref | Medline7. Kamijo, K, Murayama, H, Uzu, T, et al. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves’ disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 2010; 20: 851–856.
Google Scholar | Medline8. Giuliani, C, Cerrone, D, Harii, N, et al. A TSHr-LH/CGr chimera that measures functional TSAb in Graves’ disease. J Clin Endocrinol Metab 2012; 97: E1106–E1115.
Google Scholar | Crossref | Medline9. Scappaticcio, L, Trimboli, P, Keller, F, et al. Diagnostic testing for Graves’ or non-Graves’ hyperthyroidism: a comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography. Clin Endocrinol (Oxf) 2020; 92: 169–178.
Google Scholar | Crossref | Medline10. Cheng, X, Chai, X, Ma, C, et al. Clinical diagnostic performance of a fully automated TSI immunoassay vs . that of an automated anti-TSHR immunoassay for Graves’ disease: a Chinese multicenter study. Endocrine 2021; 71: 139–148.
Google Scholar | Crossref | Medline11. Klein, I, Becker, DV, Levey, GS. Treatment of hyperthyroid disease. Ann Intern Med 1994; 121: 281–288.
Google Scholar | Crossref | Medline12. Scappaticcio, L, Bellastella, G, Maiorino, MI, et al. Medical treatment of thyrotoxicosis. Q J Nucl Med Mol Imaging 2021; 65: 113–123.
Google Scholar | Crossref | Medline13. Mazza, E, Carlini, M, Flecchia, D, et al. Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 2008; 31: 866–872.
Google Scholar | Crossref | Medline14. Konishi, T, Okamoto, Y, Ueda, M, et al. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves’ disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J 2011; 58: 95–100.
Google Scholar | Crossref | Medline15. Kimball, LE, Kulinskaya, E, Brown, B, et al. Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest 2002; 25: 152–157.
Google Scholar | Crossref | Medline16. Allahabadia, A, Daykin, J, Holder, RL, et al. Age and gender predict the outcome of treatment for Graves’ hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038–1042.
Google Scholar | Medline17. Anagnostis, P, Adamidou, F, Polyzos, SA, et al. Predictors of long-term remission in patients with Graves’ disease: a single center experience. Endocrine 2013; 44: 448–453.
Google Scholar | Crossref | Medline18. Carella, C, Mazziotti, G. Serum thyrotropin receptor antibodies concentrations in patients with Graves’ disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid 2006; 16: 295–302.
Google Scholar | Medline19. Laurberg, P, Wallin, G, Tallstedt, L, et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69–75.
Google Scholar | Crossref | Medline20. Giuliani, C, Cerrone, D, Harii, N, et al. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment. J Clin Endocrinol Metab 2012; 97: E1080–E1107.
Google Scholar | Crossref | Medline21. Hwang, S, Shin, DY, Song, MK, et al. High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves’ disease for 12 months. Endocrine 2015; 48: 89–95.
Google Scholar | Crossref | Medline22. Kwon, H, Kim, WG, Jang, EK, et al. Usefulness of measuring thyroid stimulating antibody at the time of antithyroid drug withdrawal for predicting relapse of Graves disease. Endocrinol Metab (Seoul) 2016; 31: 300–310.
Google Scholar | Crossref | Medline23. Lytton, SD, Li, Y, Olivo, PD, et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol 2010; 162: 438–446.
Google Scholar | Crossref | Medline24. Lee, JI, Jang, HW, Kim, SK, et al. Diagnostic value of a chimeric TSH receptor (Mc4)-based bioassay for Graves’ disease. Korean J Intern Med 2011; 26: 179–186.
Google Scholar | Crossref | Medline25. Leschik, JJ, Diana, T, Olivo, PD, et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol 2013; 139: 192–200.
Google Scholar | Crossref | Medline